Genenta Science SPA
NASDAQ:GNTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marui Group Co Ltd
TSE:8252
|
JP |
Genenta Science SPA
Research & Development
Genenta Science SPA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genenta Science SPA
NASDAQ:GNTA
|
Research & Development
-€4.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Philogen SpA
MIL:PHIL
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ulisse Biomed Spa
MIL:UBM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genenta Science SPA
Glance View
Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
See Also
What is Genenta Science SPA's Research & Development?
Research & Development
-4.8m
EUR
Based on the financial report for Dec 31, 2024, Genenta Science SPA's Research & Development amounts to -4.8m EUR.
What is Genenta Science SPA's Research & Development growth rate?
Research & Development CAGR 5Y
-5%
Over the last year, the Research & Development growth was 26%. The average annual Research & Development growth rates for Genenta Science SPA have been -12% over the past three years , -5% over the past five years .
